TJ244R3 - (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment - Google Patents

(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Info

Publication number
TJ244R3
TJ244R3 TJ94000128A TJ94000128A TJ244R3 TJ 244 R3 TJ244 R3 TJ 244R3 TJ 94000128 A TJ94000128 A TJ 94000128A TJ 94000128 A TJ94000128 A TJ 94000128A TJ 244 R3 TJ244 R3 TJ 244R3
Authority
TJ
Tajikistan
Prior art keywords
oxathiolan
pyrimidin
hydroxymethyl
fluoro
amino
Prior art date
Application number
TJ94000128A
Other languages
English (en)
Inventor
Gervais Dionne
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TJ244(R3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Priority to TJ94000128A priority Critical patent/TJ244R3/xx
Publication of TJ244R3 publication Critical patent/TJ244R3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TJ94000128A 1991-08-01 1994-12-15 (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment TJ244R3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TJ94000128A TJ244R3 (en) 1991-08-01 1994-12-15 (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919116601A GB9116601D0 (en) 1991-08-01 1991-08-01 1,3-oxathiolane nucleoside analogues
PCT/CA1992/000321 WO1993003027A1 (en) 1991-08-01 1992-07-24 1,3-oxathiolane nucleoside analogues
TJ94000128A TJ244R3 (en) 1991-08-01 1994-12-15 (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Publications (1)

Publication Number Publication Date
TJ244R3 true TJ244R3 (en) 1999-11-24

Family

ID=10699340

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ94000128A TJ244R3 (en) 1991-08-01 1994-12-15 (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Country Status (40)

Country Link
US (2) US5538975A (cs)
EP (2) EP1155695B1 (cs)
JP (1) JP2960778B2 (cs)
KR (1) KR100242454B1 (cs)
CN (5) CN101074228A (cs)
AP (1) AP321A (cs)
AT (2) ATE448787T1 (cs)
AU (1) AU659668B2 (cs)
BG (1) BG61693B1 (cs)
CA (2) CA2114221C (cs)
CZ (1) CZ283765B6 (cs)
DE (2) DE69233776D1 (cs)
DK (2) DK1155695T3 (cs)
EE (1) EE03002B1 (cs)
EG (1) EG20193A (cs)
ES (2) ES2186667T3 (cs)
FI (1) FI940435A7 (cs)
GB (1) GB9116601D0 (cs)
GE (1) GEP20002094B (cs)
HN (1) HN1997000118A (cs)
HU (2) HUT70030A (cs)
IL (1) IL102616A (cs)
MA (1) MA22919A1 (cs)
MD (1) MD1434C2 (cs)
MX (1) MX9204474A (cs)
NO (3) NO300842B1 (cs)
NZ (1) NZ243637A (cs)
OA (1) OA09883A (cs)
PH (1) PH30983A (cs)
PT (2) PT1155695E (cs)
RS (1) RS49993B (cs)
RU (1) RU2126405C1 (cs)
SG (1) SG68541A1 (cs)
SK (1) SK280131B6 (cs)
TJ (1) TJ244R3 (cs)
TN (1) TNSN92070A1 (cs)
TW (2) TW366347B (cs)
WO (1) WO1993003027A1 (cs)
YU (1) YU49259B (cs)
ZA (1) ZA925668B (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2171550C (en) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
JP4413996B2 (ja) 1995-06-07 2010-02-10 エモリー・ユニバーシティ 抗ｂ型肝炎ウィルス活性を有するヌクレオシド
TW505653B (en) * 1996-02-26 2002-10-11 Meiji Seika Co Triterpene derivatives possessing an effect of treating liver diseases and pharmacentical compositions containing the same
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6071922A (en) 1997-03-19 2000-06-06 Emory University Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
US6410546B1 (en) 1997-04-07 2002-06-25 Triangle Pharmaceuticals, Inc. Use of MKC-442 in combination with other antiviral agents
ATE292631T1 (de) 1998-08-12 2005-04-15 Gilead Sciences Inc Verfahren zu herstellung von 1,3-oxathiolane nukleosiden
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
KR100632520B1 (ko) 1998-11-02 2006-10-09 길리애드 사이언시즈, 인코포레이티드 Β 형 간염 바이러스를 치료하기 위한 복합 요법
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
DK1284720T3 (da) 2000-03-29 2007-01-15 Univ Georgetown L-FMAU til behandling af hepatitis delta-virusinfektion
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
CN1503796B (zh) * 2001-03-01 2012-07-04 三角药品公司 顺-ftc的多晶型物及其它晶型
AU2002364160A1 (en) * 2001-12-14 2003-06-30 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
EP1585527A1 (en) 2003-01-14 2005-10-19 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ITMI20030578A1 (it) 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2011006892A (es) 2008-12-23 2011-07-20 Pharmasset Inc Sintesis de nucleosidos de purina.
CL2009002208A1 (es) * 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
EP3222628A1 (en) * 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
CN102482639B (zh) 2009-04-03 2016-01-06 医学研究会 活化诱导胞苷脱氨酶(aid)突变体及使用方法
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
ES2551944T3 (es) 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino
EP3449994B1 (en) 2012-01-10 2024-08-07 C.C. Jensen A/S System for cleaning degraded oil
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE2950317A1 (de) * 1979-12-14 1981-06-19 Agfa-Gevaert Ag, 5090 Leverkusen Elektrothermographische vorrichtung
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
DK0674634T3 (da) * 1989-02-08 2003-08-04 Iaf Biochem Int Fremgangsmåde til fremstilling af substituerede 1,3-oxathiolaner med antivirale egenskaber
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
HUT64844A (en) * 1991-03-06 1994-03-28 Wellcome Found Application of 5-fluorine-2'-desoxi-3'-thia-cytidine for treatment of hepatitis b
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
DK1155695T3 (da) 2010-04-06
PH30983A (en) 1997-12-23
RS49993B (sr) 2008-09-29
CN1302612A (zh) 2001-07-11
NO2005017I2 (no) 2007-10-01
SK280131B6 (sk) 1999-08-06
CA2114221A1 (en) 1993-02-18
BG98616A (bg) 1995-03-31
EG20193A (en) 1997-10-30
CA2114221C (en) 2009-12-22
NO940322L (no) 1994-03-21
KR100242454B1 (ko) 2000-03-02
IL102616A0 (en) 1993-01-14
CZ20394A3 (en) 1994-07-13
GEP20002094B (en) 2000-05-10
EP0526253A1 (en) 1993-02-03
CN101074228A (zh) 2007-11-21
NO300842B1 (no) 1997-08-04
RU2126405C1 (ru) 1999-02-20
HK1038189A1 (en) 2002-03-08
PT1155695E (pt) 2010-02-02
EE03002B1 (et) 1997-06-16
EP1155695B1 (en) 2009-11-18
HU211333A9 (en) 1995-11-28
MD1434C2 (ro) 2000-12-31
NZ243637A (en) 1995-03-28
FI940435L (fi) 1994-01-28
TW366347B (en) 1999-08-11
JP2960778B2 (ja) 1999-10-12
MD950114A (en) 1996-06-28
EP0526253B1 (en) 2002-11-13
HK1008672A1 (en) 1999-05-14
YU49259B (sh) 2004-12-31
TWI232217B (en) 2005-05-11
FI940435A0 (fi) 1994-01-28
CA2682254C (en) 2012-02-21
JPH07500317A (ja) 1995-01-12
CA2682254A1 (en) 1993-02-18
AP9200414A0 (en) 1992-07-31
PT526253E (pt) 2003-03-31
CN1074924C (zh) 2001-11-21
MA22919A1 (fr) 1993-04-01
MD1434B2 (en) 2000-03-31
CN1132073A (zh) 1996-10-02
CN1070191A (zh) 1993-03-24
ES2186667T3 (es) 2003-05-16
YU74992A (sh) 1995-12-04
AU659668B2 (en) 1995-05-25
MX9204474A (es) 1993-12-01
GB9116601D0 (en) 1991-09-18
NO2005017I1 (no) 2005-09-05
CN100542535C (zh) 2009-09-23
NO940322D0 (no) 1994-01-31
ZA925668B (en) 1993-04-28
TNSN92070A1 (fr) 1993-06-08
CN101066970A (zh) 2007-11-07
AU2340892A (en) 1993-03-02
ES2335968T3 (es) 2010-04-07
HUT70030A (en) 1995-09-28
CN1034810C (zh) 1997-05-07
DK0526253T3 (da) 2003-03-17
US5538975A (en) 1996-07-23
EP1155695A1 (en) 2001-11-21
ATE448787T1 (de) 2009-12-15
SG68541A1 (en) 1999-11-16
DE69232845T2 (de) 2003-04-24
DE69233776D1 (de) 2009-12-31
US5618820A (en) 1997-04-08
ATE227720T1 (de) 2002-11-15
NO2008009I1 (no) 2008-06-30
CZ283765B6 (cs) 1998-06-17
DE69232845D1 (de) 2002-12-19
AP321A (en) 1994-02-28
HN1997000118A (es) 1999-11-12
WO1993003027A1 (en) 1993-02-18
IL102616A (en) 1996-10-31
BG61693B1 (bg) 1998-03-31
HU9400285D0 (en) 1994-05-30
SK10494A3 (en) 1994-12-07
YU72303A (sh) 2006-05-25
FI940435A7 (fi) 1994-01-28
OA09883A (en) 1994-09-15

Similar Documents

Publication Publication Date Title
TJ244R3 (en) (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment
NZ238017A (en) (-)-cis-4-amino-1 -(2-hydroxymethyl -1,3-oxathiolan-5-yl) -(1h)- pyrimidin-2-one, preparation and pharmaceutical compositions
HU9302377D0 (en) Method for preparing medical preparatives of antiviral effect as well as one for resolving 2-(hydroxi-methyl)-5-(5-fluorine-cytosine-1-yl)-1,3-oxathiolane
NZ232421A (en) Purine or pyrimidine substituted 1,3-oxathiolane derivatives; preparatory process, intermediates and pharmaceutical compositions
HUT49592A (en) Process for producing bis/hydroxymethyl/-cyclobutyl-purines and pyrimidines, as well as pharmaceutical compositions comprising same
CA2311988A1 (en) Crystalline oxathiolane derivatives
FI20030933A7 (fi) 1,3-oksatiolaani ja menetelmä sen valmistamiseksi
HUT65374A (en) Process for producing of dialkylene-piperidino compounds,their enantiomers and pharmaceutical compositions comprising them
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
DE69400256D1 (de) Verfahren zur Herstellung von mit Carbonat angereicherten Hydroxyapatit Zusammensetzungen
AU6924796A (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
PL295673A2 (en) Method of obtaining novel derivatives of 1,4-benzodioxane
FI913957A7 (fi) 6,7-dihydro-3-fenyyli-1,2-bentsisoksatsol-4(5H)-oneja ja -oleja, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä
HUT48216A (en) Insecticidal, nematocidal, coccidiostatic compositions comprising n-phenylpyrazole derivatives and process for producing the active ingredients
BR9405206A (pt) Composto,composição para fumar,composição apropriada para consumo humano,processo para a produção de compostos,e processo para aromatizar tabaco
PL300016A1 (en) 1,4 derivatives of benzodioxane, method of obtaining them as well as pharmaceutical preparation and method of obtaining same
GB9221234D0 (en) Stemmed flower-like decorating
HU9203939D0 (en) Isoxazolyl-imidazole derivatives, method for producing them and their application as medicament
AU6968791A (en) Oxipurinol salt composition for oral administration for treating hyperurecemia
FI954183A0 (fi) Menetelmä valmistaa cis-4-amino-1-(2-hydroksimetyyli-1,3-oksatiolan-5-yyli)-(1H)-pyrimidin-2-onin (-)enantiomeeriä käytettäväksi virustenvastaisena aineena
BR8705401A (pt) Composicao de ajuste de sabor
IT8948600A0 (it) Composizione per la profilassi anticarie dello smalto umano
GB9219155D0 (en) A composition for the treatment of game birds,particularly grouse
IL94856A0 (en) Method of preparing(+)-(2s,3s)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-5h-1,5-benzothiazepine-4-one and chlorinated derivatives thereof
EP0537591A3 (en) Process for the preparation of 1,2-bis-(2-nitrophenoxy)-ethane